Free Trial
Your Rate Never Goes Up! Save $100 a Year on MarketBeat All Access
Upgrade Now
Claim MarketBeat All Access Sale Promotion

Healthcare Stocks List

This page shows information about the 50 largest healthcare sector stocks including Eli Lilly and Company, Johnson & Johnson, AbbVie and UnitedHealth Group.

Eli Lilly and Company stock logo

1. Eli Lilly and Company NYSE:LLY

$1,275.50 -31.19 (-2.39%)
Closing price 10/23/2026 03:59 PM Eastern
Extended Trading
$1,278.93 +3.43 (+0.27%)
As of 10/23/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. More about Eli Lilly and Company

Pros of Eli Lilly and Company

  • Eli Lilly and Co shares are trading at $1,308.21, a 2.9% increase on the day, reflecting strong market confidence as the stock approaches its 52-week high of $1,321.21. This price action indicates that investors are willing to pay a premium for the company's growth trajectory, with the current valuation supported by a P/E ratio of 43.90 and a market capitalization of $1.23 trillion.
  • The company recently broke ground on a new $5 billion manufacturing facility in Virginia, which is part of a broader $50 billion expansion of U.S. production. This site will be the first fully integrated facility to produce both active pharmaceutical ingredients and finished medicines, including next-generation cancer treatments, which should improve long-term supply capacity and reduce manufacturing bottlenecks.
  • Eli Lilly and Co has secured a strategic partnership with UAE-based Mubadala Bio for the packaging, logistics, and advanced pharmaceutical contract manufacturing of GLP-1 medicines in Abu Dhabi. This agreement supports the international distribution of key weight-loss products like Mounjaro and expands the company's regional presence in the Middle East.

Cons of Eli Lilly and Company

  • Analysts expect Eli Lilly and Co's upcoming third-quarter earnings to decline, with a Zacks preview noting that the company lacks the typical combination of estimate revisions and earnings momentum associated with a likely beat. This raises the risk of disappointment for investors after the stock's strong recent run to new highs.
  • Recent revenue growth has been driven primarily by higher volume rather than pricing, as second-quarter sales rose 48% while medicine volume increased 60%, but average prices fell 13%. This continued price pressure could weigh on margins and make future growth increasingly dependent on prescription volume rather than pricing power.
  • Competitive pressure is intensifying in the obesity treatment market, with Novo Nordisk's CagriSema reportedly producing 25% weight loss in women. This highlights a potentially stronger competing treatment that could challenge Eli Lilly and Co's dominant position in its GLP-1 franchise and impact future market share.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$1.20 trillion
P/E Ratio
42.80
Consensus Rating
Moderate Buy
Consensus Price Target
$1,317.93 (+3.3% Upside)
Volume
2.27 million shares
Average Volume
2.30 million shares
Today's Range
$1,257.62
▼
$1,307.92
50-Day Range
$1,115.53
▼
$1,308.21
52-Week Range
$809.63
▼
$1,321.21
Dividend Yield
0.53%
Johnson & Johnson stock logo

2. Johnson & Johnson NYSE:JNJ

$264.13 -3.48 (-1.30%)
Closing price 10/23/2026 03:59 PM Eastern
Extended Trading
$263.45 -0.68 (-0.26%)
As of 10/23/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. More about Johnson & Johnson

Pros of Johnson & Johnson

  • Johnson & Johnson recently secured regulatory approval in the United Kingdom for its oral psoriasis treatment, a significant expansion of its commercial opportunity in a major market that strengthens the immunology pipeline and supports long-term growth in the Innovative Medicine segment.
  • The company demonstrated strong earnings resilience by reporting $2.59 in earnings per share for the quarter ended October 13, 2026, which beat the consensus estimate of $2.53, while revenue grew 5.9% year-over-year to $25.40 billion, indicating solid core business performance despite broader market challenges.
  • Investors can benefit from the company's defensive profile, as evidenced by a low beta of 0.21, which measures the stock's volatility relative to the overall market, suggesting that Johnson & Johnson shares may provide stability and lower risk during periods of broader large-cap weakness.

Cons of Johnson & Johnson

  • The company faces valuation concerns with a price-to-earnings ratio of 40.02, which is considered premium, and Erste Group Bank recently downgraded the stock to Hold, citing falling earnings estimates and MedTech execution risks that may limit near-term price appreciation.
  • Recent insider activity shows a trend of selling, with executives such as Timothy Schmid and Jennifer L. Taubert selling a combined 48,597 shares in the last few months, which may signal a lack of confidence in the stock's short-term trajectory from those closest to the company's operations.
  • Strategic opportunities have been lost, as reported merger talks between Johnson & Johnson's orthopedics business and Smith & Nephew collapsed over a leadership dispute, removing potential synergies and raising questions about the company's execution capabilities in the MedTech sector.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$635.07 billion
P/E Ratio
40.02
Consensus Rating
Moderate Buy
Consensus Price Target
$275.92 (+4.5% Upside)
Volume
5.31 million shares
Average Volume
7.84 million shares
Today's Range
$262.40
▼
$266.03
50-Day Range
$248.90
▼
$278.66
52-Week Range
$184.66
▼
$281.07
Dividend Yield
2.00%
AbbVie stock logo

3. AbbVie NYSE:ABBV

$285.66 +0.47 (+0.16%)
Closing price 10/23/2026 03:59 PM Eastern
Extended Trading
$285.27 -0.39 (-0.14%)
As of 10/23/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. More about AbbVie

Pros of AbbVie

  • AbbVie received FDA approval on October 23, 2026, for a subcutaneous induction regimen for SKYRIZI in Crohn's disease, a significant expansion that supports early symptomatic control and strengthens the company's immunology portfolio against competitors.
  • The stock is currently trading at $285.66, which is near its 52-week high of $291.40, reflecting strong recent momentum and a consensus rating of Moderate Buy with a price target of $278.07, indicating analyst confidence in the company's trajectory.
  • AbbVie reported Q2 2026 revenue of $16.99 billion, beating estimates of $16.80 billion and growing 10.2% year-over-year, demonstrating robust commercial execution and demand for its key products like Skyrizi and Rinvoq.

Cons of AbbVie

  • Analysts have recently lowered earnings forecasts, with Erste Group Bank reducing its FY2026 EPS estimate to $13.90 from $14.00, and the consensus estimate for full-year earnings has dropped to $13.94, signaling potential pressure on profitability.
  • The stock trades at a P/E ratio of 80.69, which is significantly high and suggests that the market is pricing in substantial future growth, leaving little room for error if earnings disappoint or if the company faces patent cliff challenges.
  • AbbVie halted an early-stage liver cancer combination trial, a setback in its oncology pipeline that may limit near-term growth opportunities in that therapeutic area and raise questions about the success rate of its newer drug candidates.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$504.67 billion
P/E Ratio
80.69
Consensus Rating
Moderate Buy
Consensus Price Target
$279.86 (-2.0% Downside)
Volume
4.63 million shares
Average Volume
5.20 million shares
Today's Range
$282.30
▼
$286.77
50-Day Range
$248.75
▼
$288.66
52-Week Range
$190.75
▼
$291.40
Dividend Yield
2.42%
UnitedHealth Group stock logo

4. UnitedHealth Group NYSE:UNH

$417.97 -7.01 (-1.65%)
Closing price 10/23/2026 03:59 PM Eastern
Extended Trading
$418.20 +0.23 (+0.05%)
As of 10/23/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. More about UnitedHealth Group

Pros of UnitedHealth Group

  • UnitedHealth Group demonstrated significant financial strength in its most recent quarter, reporting adjusted earnings per share of $4.69, which exceeded the analyst consensus estimate of $4.14 by $0.55. This strong performance was accompanied by a 61% year-over-year increase in adjusted earnings, signaling a robust recovery in profitability for the healthcare conglomerate.
  • The company's operational efficiency has improved markedly, as evidenced by the medical care ratio improving to 88.4%. This metric indicates that UnitedHealth Group is retaining a larger portion of its premium revenue after covering medical costs, which directly supports higher margins and overall financial health.
  • Wall Street sentiment remains positive, with the stock currently trading at $425.29, a price that is below the consensus price target of $463.80. This valuation gap suggests potential for further upside, supported by a "Moderate Buy" consensus rating from twenty analysts who have issued Buy ratings compared to eight Hold ratings.

Cons of UnitedHealth Group

  • UnitedHealth Group is expected to raise 2027 Medicare costs for seniors, which could lead to increased premiums and prescription-drug costs for older Americans. This move may create affordability concerns and invite regulatory scrutiny, potentially impacting the company's public perception and political standing.
  • Despite the recent earnings beat, the company's quarterly revenue of $112.70 billion was down 0.4% compared to the same quarter last year. This slight decline in top-line growth suggests that the company may be facing headwinds in expanding its customer base or increasing service volumes, even as profitability improves.
  • Healthcare sector weakness remains a near-term headwind, as healthcare stocks have recently moved lower, suggesting that some of UnitedHealth Group's gains may be vulnerable to sector-wide trading pressure. This broader market sentiment could limit the stock's ability to sustain its recent rally.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$375.28 billion
P/E Ratio
23.87
Consensus Rating
Moderate Buy
Consensus Price Target
$463.80 (+11.0% Upside)
Volume
3.89 million shares
Average Volume
6.06 million shares
Today's Range
$416.37
▼
$425.25
50-Day Range
$365.24
▼
$425.29
52-Week Range
$255.96
▼
$461.62
Dividend Yield
2.18%
Merck & Co., Inc. stock logo

5. Merck & Co., Inc. NYSE:MRK

$145.25 -1.99 (-1.35%)
Closing price 10/23/2026 03:59 PM Eastern
Extended Trading
$145.40 +0.15 (+0.10%)
As of 10/23/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. More about Merck & Co., Inc.

Pros of Merck & Co., Inc.

  • Merck recently secured European Commission approval for KEYTRUDA plus Padcev as a perioperative treatment for resectable muscle-invasive bladder cancer, marking the first EU authorization for a PD-1 inhibitor combined with an antibody-drug conjugate in this setting, which broadens the addressable patient population and supports future revenue growth for the company's flagship oncology drug.
  • The company reported positive Phase 3 results for the INTerpath-001 trial of the personalized cancer vaccine intismeran autogene combined with KEYTRUDA in melanoma, showing a 42% reduction in the risk of recurrence or death, which strengthens the long-term potential of Merck's oncology pipeline and provides a new therapeutic avenue beyond its current blockbuster products.
  • Merck offers a dividend yield of 2.27% with a recent quarterly payment of $0.85 per share, providing a steady income stream for investors, while the stock's low beta of 0.21 suggests it may offer lower volatility compared to the broader market, making it an attractive option for risk-averse portfolios seeking stability.

Cons of Merck & Co., Inc.

  • Merck faces significant risk from the upcoming patent cliff for KEYTRUDA, its most profitable drug, which could lead to a substantial decline in revenue and earnings as generic competitors enter the market, potentially impacting the company's ability to maintain its current dividend and growth trajectory.
  • The company's dividend payout ratio is currently 272.00%, meaning Merck is paying out more in dividends than it is earning in net income, which raises concerns about the sustainability of the dividend and the company's financial health, especially as it navigates the transition from its legacy products to new growth drivers.
  • Recent insider selling activity has been notable, with executives like EVP Jennifer Zachary and EVP David R. Maraldo selling significant portions of their holdings in August 2026, which may signal a lack of confidence in the stock's near-term performance or a desire to diversify personal wealth away from the company.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$358.41 billion
P/E Ratio
116.20
Consensus Rating
Moderate Buy
Consensus Price Target
$151.92 (+4.6% Upside)
Volume
8.38 million shares
Average Volume
9.66 million shares
Today's Range
$143.41
▼
$145.44
50-Day Range
$135.34
▼
$156.54
52-Week Range
$82.01
▼
$156.92
Dividend Yield
2.34%
Novartis stock logo

6. Novartis NYSE:NVS

$151.05 -5.22 (-3.34%)
Closing price 10/23/2026 03:59 PM Eastern
Extended Trading
$153.00 +1.95 (+1.29%)
As of 10/23/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. More about Novartis

Pros of Novartis

  • Novartis AG recently presented six-year data for its breast cancer drug Kisqali, demonstrating a 19% reduction in the risk of death, which validates the long-term efficacy and commercial potential of a key asset in the company's oncology portfolio.
  • The company secured European Union approval for Cosentyx in the treatment of polymyalgia rheumatica, expanding the therapeutic reach of this immunology blockbuster and providing a new revenue stream in a competitive market.
  • Novartis AG is trading at a current stock price of $151.05, which is below the average analyst price target of $145.60, suggesting that the stock may be undervalued relative to Wall Street's consensus expectations for its future performance.

Cons of Novartis

  • Novartis AG recently disclosed weaker-than-expected relapse data for its multiple sclerosis drug remibrutinib in Phase 3 trials, which could dampen investor confidence in the company's pipeline and future growth prospects in the neuroscience space.
  • The company halted its Phase 2 study of iptacopan in lupus nephritis, representing a setback in its renal and metabolic disease portfolio and potentially delaying the realization of revenue from this therapeutic area.
  • Novartis AG is scheduled to release its Q3 2026 earnings on October 27, 2026, and the stock has already declined as investors lock in gains ahead of the report, indicating potential near-term volatility and uncertainty surrounding the company's financial performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$288.36 billion
P/E Ratio
22.78
Consensus Rating
Hold
Consensus Price Target
$145.60 (-3.6% Downside)
Volume
4.36 million shares
Average Volume
1.75 million shares
Today's Range
$149.17
▼
$156.08
50-Day Range
$137.22
▼
$163.27
52-Week Range
$121.57
▼
$170.46
Dividend Yield
2.04%
Astrazeneca stock logo

7. Astrazeneca NYSE:AZN

$171.56 -1.01 (-0.58%)
Closing price 10/23/2026 03:59 PM Eastern
Extended Trading
$170.70 -0.87 (-0.51%)
As of 10/23/2026 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Market Capitalization
$265.97 billion
P/E Ratio
25.64
Consensus Rating
Moderate Buy
Consensus Price Target
$206.67 (+20.5% Upside)
Volume
3.69 million shares
Average Volume
2.85 million shares
Today's Range
$169.51
▼
$171.75
50-Day Range
$155.93
▼
$172.64
52-Week Range
$153.41
▼
$212.71
Dividend Yield
2.51%
Thermo Fisher Scientific stock logo

8. Thermo Fisher Scientific NYSE:TMO

$673.96 -2.58 (-0.38%)
Closing price 10/23/2026 03:59 PM Eastern
Extended Trading
$676.39 +2.42 (+0.36%)
As of 10/23/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. More about Thermo Fisher Scientific

Pros of Thermo Fisher Scientific

  • Thermo Fisher Scientific Inc. recently reported third-quarter revenue of $12.14 billion, which was up 9.1% year over year, while adjusted earnings per share of $6.68 exceeded the consensus estimate of $6.40, demonstrating strong operational performance and the ability to beat market expectations.
  • Management raised its full-year 2026 revenue-growth and earnings outlook following the recent earnings release, signaling confidence in the company's trajectory and suggesting that the current recovery across clinical research, bioproduction, and laboratory products is sustainable.
  • Analysts have shown strong bullish sentiment, with TD Cowen raising its price target to $810 and Stifel Nicolaus lifting its target to $775, reflecting a consensus view that the stock is undervalued relative to its fundamental improvements and industry growth potential.

Cons of Thermo Fisher Scientific

  • Despite the strong earnings report, the stock price reaction has been muted, with the share price only up about 1% after the release, indicating that investors may be demanding clearer evidence that the end-market recovery can justify the stock's elevated earnings multiple.
  • Heavy put-option buying, including activity roughly 52% above average, suggests that some traders are hedging against a potential pullback or positioning defensively, signaling caution among market participants regarding the stock's near-term direction.
  • Corporate insiders have been selling shares, with the CEO Marc N. Casper selling 10,000 shares at an average price of $629.27 in August 2026, and other executives like COO Gianluca Pettiti also reducing their holdings, which can be interpreted as a lack of confidence in the current valuation.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$249.14 billion
P/E Ratio
35.55
Consensus Rating
Moderate Buy
Consensus Price Target
$681.00 (+1.0% Upside)
Volume
2.04 million shares
Average Volume
2.45 million shares
Today's Range
$662.50
▼
$677.28
50-Day Range
$586.62
▼
$695.75
52-Week Range
$435.27
▼
$705.78
Dividend Yield
0.28%
Amgen stock logo

9. Amgen NASDAQ:AMGN

$439.26 -8.02 (-1.79%)
Closing price 10/23/2026 04:00 PM Eastern
Extended Trading
$442.00 +2.74 (+0.62%)
As of 10/23/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. More about Amgen

Pros of Amgen

  • Amgen Inc. recently reported strong third-quarter results, beating analyst expectations with earnings per share of $6.29 against a consensus of $5.62 and revenue of $10.05 billion, which exceeded the estimated $9.43 billion, demonstrating robust fundamental performance and year-over-year revenue growth of 9.5%.
  • The company has raised its full-year 2026 earnings guidance to a range of $22.30 to $23.50 per share, signaling management confidence in continued growth, while the stock currently trades at $439.26, reflecting a significant 55% increase from its October lows and highlighting strong investor momentum.
  • Amgen Inc. provides a stable income stream with a dividend yield of 2.30%, having recently paid a quarterly dividend of $2.52 per share, which offers a reliable return for income-focused investors despite the stock's recent price appreciation.

Cons of Amgen

  • The stock's current price of $439.26 is significantly above the consensus price target of $387.93, suggesting that the stock may be overvalued relative to Wall Street's average expectations, which could limit future upside potential.
  • Amgen Inc. carries a high debt-to-equity ratio of 4.44, indicating substantial leverage that could pose financial risks if interest rates remain elevated or if the company faces unexpected operational challenges, potentially impacting its ability to service debt.
  • Recent insider activity shows a trend of selling, with senior executives like Rachna Khosla and Nancy A. Grygiel reducing their holdings in August 2026, which may signal a lack of confidence in the stock's near-term performance or a desire to lock in gains.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$237.48 billion
P/E Ratio
27.30
Consensus Rating
Hold
Consensus Price Target
$389.71 (-11.3% Downside)
Volume
2.07 million shares
Average Volume
2.76 million shares
Today's Range
$439.07
▼
$444.59
50-Day Range
$375.65
▼
$447.28
52-Week Range
$288.00
▼
$450.98
Dividend Yield
2.25%
Gilead Sciences stock logo

10. Gilead Sciences NASDAQ:GILD

$156.04 -1.15 (-0.73%)
Closing price 10/23/2026 04:00 PM Eastern
Extended Trading
$156.99 +0.95 (+0.61%)
As of 10/23/2026 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. More about Gilead Sciences

Pros of Gilead Sciences

  • Gilead Sciences, Inc. recently agreed to acquire PepStar Therapeutics' investigational oral IL-23R inhibitor program, including HCXT-2001, for approximately $1.275 billion in cash, which strengthens the company's inflammation pipeline and positions it to compete in the inflammatory bowel disease market alongside its own emvistegrast asset.
  • The company is currently trading at $156.04, a level that reflects a significant year-to-date gain of 28.32% and a 90-day return of 20.67%, indicating strong recent momentum and sustained investor confidence in its biopharmaceutical portfolio.
  • Analysts maintain a Moderate Buy consensus with a price target of $159.63, and recent updates from firms like Erste Group Bank and TD Cowen suggest that Gilead Sciences, Inc. is well-positioned to meet or exceed earnings expectations, supported by a robust pipeline that includes new data on rare liver diseases to be presented at The Liver Meeting 2026.

Cons of Gilead Sciences

  • The company faces a negative price-to-earnings ratio of -58.44, which indicates that it is currently reporting a net loss, a situation that can deter value-oriented investors and suggests that profitability is not yet consistent with its market valuation.
  • Gilead Sciences, Inc. is required to pay a $45 million settlement to resolve Texas Medicaid claims alleging unlawful incentives to encourage providers to prescribe its medicines, which introduces regulatory and reputational risks that could impact future operations and investor sentiment.
  • Insider selling has been consistent and significant, with CEO Daniel O'Day selling 15,000 shares in October 2026 and CFO Andrew Dickinson selling 3,000 shares in the same period, which may signal that company executives are taking advantage of the recent stock price appreciation to reduce their personal exposure.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$193.48 billion
P/E Ratio
N/A
Consensus Rating
Moderate Buy
Consensus Price Target
$159.81 (+2.4% Upside)
Volume
6.07 million shares
Average Volume
5.70 million shares
Today's Range
$155.76
▼
$157.65
50-Day Range
$138.92
▼
$157.37
52-Week Range
$114.02
▼
$160.51
Dividend Yield
2.09%
Abbott Laboratories stock logo

11. Abbott Laboratories NYSE:ABT

$103.70 +1.19 (+1.16%)
Closing price 10/23/2026 03:59 PM Eastern
Extended Trading
$103.76 +0.06 (+0.05%)
As of 10/23/2026 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. More about Abbott Laboratories

Pros of Abbott Laboratories

  • Abbott Laboratories recently presented new data at the European Society for Medical Oncology showing that its Oncodetect test delivered a 30% absolute improvement in sensitivity for detecting colorectal-cancer recurrence within two years of surgery, which supports the clinical value of the company's molecular diagnostics strategy and could drive future demand in the cancer-care market.
  • Wall Street analysts maintain a positive outlook on the stock, with Wells Fargo upgrading its stance to "overweight" and raising its price target to $119, while the consensus rating remains a "Moderate Buy" with an average price target of $118.32, suggesting that the current market price of $103.70 offers substantial potential upside relative to professional estimates.
  • The company reported third-quarter earnings of $1.42 per share, which met analyst consensus estimates, and generated revenue of $13.01 billion, slightly exceeding the $12.99 billion expected by analysts, demonstrating that the business is maintaining its financial performance despite broader market concerns.

Cons of Abbott Laboratories

  • Investors remain concerned about Abbott's lowered 2026 sales-growth outlook, as management cited diabetes-related pricing pressure and weakness in the electrophysiology portfolio, which are issues that overshadowed the recent earnings performance and may limit future revenue growth.
  • Abbott plans to spin off its approximately $8.5 billion Nutrition business by 2027, a move that introduces near-term uncertainty for investors regarding separation costs, changes in portfolio mix, and the growth profile of the remaining business, potentially distracting management and affecting short-term stability.
  • A comparative study claimed that Catheter Precision’s LockeT device outperformed Abbott’s Perclose vascular-closure system, which adds competitive pressure to Abbott’s medical-device franchise and could impact its market share in the vascular closure segment.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$179.44 billion
P/E Ratio
38.70
Consensus Rating
Moderate Buy
Consensus Price Target
$118.32 (+14.1% Upside)
Volume
10.30 million shares
Average Volume
10.07 million shares
Today's Range
$101.56
▼
$104.00
50-Day Range
$96.62
▼
$116.70
52-Week Range
$81.97
▼
$132.02
Dividend Yield
2.46%
Novo Nordisk A/S stock logo

12. Novo Nordisk A/S NYSE:NVO

$39.05 -0.38 (-0.97%)
Closing price 10/23/2026 03:59 PM Eastern
Extended Trading
$39.02 -0.03 (-0.07%)
As of 10/23/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. More about Novo Nordisk A/S

Pros of Novo Nordisk A/S

  • Novo Nordisk's next-generation obesity drug, CagriSema, demonstrated an average 25% reduction in body weight after 68 weeks in a late-stage analysis of women with obesity or overweight, strengthening the company's long-term position in the expanding obesity-treatment market and potentially serving as a successor to Wegovy.
  • The company recently received FDA approval for Awiqli, which is the first and only once-weekly insulin for children 10 years of age and older with type 2 diabetes, providing a differentiated product in the diabetes care segment.
  • Novo Nordisk expanded its 2026 share buyback program, increasing its treasury-share stake to 1.2%, which signals management's confidence in the company's value and may support earnings per share by reducing the number of shares outstanding.

Cons of Novo Nordisk A/S

  • Investors continue to assess rising competition from Eli Lilly and Viking Therapeutics, along with risks from drug-pricing pressure, intellectual-property challenges, and declining earnings estimates, which help explain why the stock remains under pressure despite promising clinical results.
  • Several institutional investors have recently reduced their stakes in the company, including Smith Chas P & Associates PA Cpas which cut its stake by 99.3% in the 3rd quarter, and Quadrant Capital Group LLC which trimmed its stake by 44.7%, indicating a lack of confidence among some major holders.
  • Novo Nordisk recently cut its dividend, paying $0.5786 per share in August 2026, which is a significant negative change from the previous dividend of $1.2751, potentially disappointing income-focused investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$174.36 billion
P/E Ratio
9.55
Consensus Rating
Hold
Consensus Price Target
$59.44 (+52.2% Upside)
Volume
9.18 million shares
Average Volume
11.40 million shares
Today's Range
$38.75
▼
$39.29
50-Day Range
$37.31
▼
$48.65
52-Week Range
$35.12
▼
$64.16
Dividend Yield
2.09%
Pfizer stock logo

13. Pfizer NYSE:PFE

$30.04 -0.39 (-1.27%)
Closing price 10/23/2026 03:59 PM Eastern
Extended Trading
$30.02 -0.01 (-0.04%)
As of 10/23/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. More about Pfizer

Pros of Pfizer

  • Pfizer Inc. recently announced robust Phase 2 data for its investigational 25-valent pneumococcal conjugate vaccine candidate, PF-07872412, which elicited strong immune responses against all 25 serotypes in infants with a safety profile comparable to the existing Prevnar 20 vaccine, signaling a significant pipeline advancement for the company's infectious disease franchise.
  • The company signed a research collaboration and licensing agreement with Enodia Therapeutics focused on small-molecule Sec61 inhibitors, granting Pfizer rights to discover and develop potential oncology and specialty treatments, which adds new value to its longer-term pipeline and diversifies its growth opportunities beyond current core products.
  • With a current stock price of $30.04, Pfizer Inc. offers a dividend yield of 5.65%, which is among the highest in the S&P 500, providing a substantial income stream for investors that compares favorably with peers like Merck, despite the stock trading near its 52-week high of $30.44.

Cons of Pfizer

  • Pfizer Inc. has a dividend payout ratio of 226.32%, meaning the company is paying out more in dividends than it is earning in net income, which raises concerns about the sustainability of the high yield and suggests that the dividend may be at risk if earnings do not improve significantly.
  • The consensus rating from Wall Street analysts is "Hold" with an average price target of $28.72, which is below the current stock price of $30.04, indicating that analysts believe the stock is currently overvalued relative to its expected future performance and potential for growth.
  • Recent comparisons with Bristol Myers Squibb highlight Pfizer Inc.'s uneven revenue performance, including year-over-year declines in several recent quarters, such as a 1.2% revenue drop in the quarter ending February 2026, suggesting that the company's growth trajectory is less consistent than some of its competitors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$171.16 billion
P/E Ratio
39.52
Consensus Rating
Hold
Consensus Price Target
$28.72 (-4.4% Downside)
Volume
29.45 million shares
Average Volume
29.68 million shares
Today's Range
$29.81
▼
$30.32
50-Day Range
$26.88
▼
$30.40
52-Week Range
$23.62
▼
$30.44
Dividend Yield
5.65%
Danaher stock logo

14. Danaher NYSE:DHR

$230.36 +0.61 (+0.27%)
Closing price 10/23/2026 03:59 PM Eastern
Extended Trading
$230.67 +0.31 (+0.14%)
As of 10/23/2026 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. More about Danaher

Pros of Danaher

  • Danaher Co. recently reported third-quarter adjusted earnings of $2.11 per share, which significantly exceeded the analyst consensus estimate of $1.92, demonstrating strong profitability and operational efficiency that can drive shareholder value.
  • Following the strong earnings report, major financial institutions such as TD Cowen, JPMorgan, and Goldman Sachs raised their price targets to between $270 and $275, indicating that Wall Street expects the stock to appreciate further from its current price of $230.36.
  • The company has raised its full-year 2026 adjusted earnings per share outlook, signaling management confidence in sustained growth and the ability to deliver higher profits to investors over the coming months.

Cons of Danaher

  • Despite beating earnings estimates, the stock price declined in the immediate aftermath of the results, suggesting that investors may have already priced in the positive news and are skeptical about future upside potential.
  • The company is facing pressure from tariffs and has a cautious outlook for 2027, which creates uncertainty regarding future cost structures and profitability beyond the current fiscal year.
  • Danaher Co. trades at a price-to-earnings ratio of 37.70, which is relatively high compared to many peers, meaning investors are paying a premium for growth that may not be sustained if execution issues arise.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$162.16 billion
P/E Ratio
37.70
Consensus Rating
Moderate Buy
Consensus Price Target
$242.91 (+5.4% Upside)
Volume
3.94 million shares
Average Volume
4.91 million shares
Today's Range
$225.60
▼
$230.66
50-Day Range
$199.62
▼
$233.99
52-Week Range
$160.93
▼
$242.80
Dividend Yield
0.69%
Intuitive Surgical stock logo

15. Intuitive Surgical NASDAQ:ISRG

$452.29 +8.44 (+1.90%)
Closing price 10/23/2026 04:00 PM Eastern
Extended Trading
$452.05 -0.24 (-0.05%)
As of 10/23/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. More about Intuitive Surgical

Pros of Intuitive Surgical

  • Intuitive Surgical, Inc. recently reported third-quarter revenue of approximately $3.05 billion, which represents a 21.7% increase year over year and significantly exceeded the analyst consensus estimate of $2.91 billion, demonstrating strong top-line growth momentum.
  • The company delivered earnings per share of $3.00 for the quarter, beating the consensus estimate of $2.65 by $0.35, indicating that the business is generating higher profits than expected despite recent cost pressures.
  • Intuitive Surgical, Inc. was upgraded to a Strong Buy rating by Zacks Research on October 24, 2026, and added to the Zacks Rank #1 list, signaling that quantitative models now view the stock as having a high probability of outperforming the market.

Cons of Intuitive Surgical

  • U.S. da Vinci procedure growth has slowed to its lowest level since the COVID period, raising concerns that decelerating domestic demand could make it difficult for the company to sustain its premium valuation.
  • The company's P/E ratio stands at 54.69, which is significantly higher than the broader market average, meaning investors are paying a high price for each dollar of earnings and leaving little room for error if growth slows further.
  • Third-quarter results included roughly $450 million in costs tied to an antitrust settlement, which reduced margins and highlights the financial impact of legal and regulatory challenges on near-term profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$156.78 billion
P/E Ratio
54.69
Consensus Rating
Moderate Buy
Consensus Price Target
$493.54 (+9.1% Upside)
Volume
3.00 million shares
Average Volume
2.25 million shares
Today's Range
$442.56
▼
$458.45
50-Day Range
$350.16
▼
$452.29
52-Week Range
$328.57
▼
$603.88
Dividend Yield
N/A
Vertex Pharmaceuticals stock logo

16. Vertex Pharmaceuticals NASDAQ:VRTX

$523.93 -11.24 (-2.10%)
Closing price 10/23/2026 04:00 PM Eastern
Extended Trading
$524.88 +0.95 (+0.18%)
As of 10/23/2026 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). More about Vertex Pharmaceuticals

Pros of Vertex Pharmaceuticals

  • Vertex Pharmaceuticals Incorporated recently presented Phase III RAINIER trial data at the American Society of Nephrology Kidney Week 2026, demonstrating that its drug povetacicept reduced proteinuria by 52% in patients with IgA nephropathy, a result that supports the company's strategy to diversify beyond its cystic fibrosis franchise and establish a new growth engine in kidney disease.
  • The stock currently trades at $523.93, which is below the consensus price target of $579.81 set by analysts who maintain a Moderate Buy rating, suggesting that the market may be undervaluing the company's potential for future earnings growth as it expands its pipeline into new therapeutic areas.
  • Vertex Pharmaceuticals Incorporated reported strong financial performance in its most recent quarter with revenue of $3.33 billion, exceeding the consensus estimate of $3.23 billion, and achieved a net margin of 35.00%, indicating robust profitability and operational efficiency that can support shareholder value even as the company invests in new drug development.

Cons of Vertex Pharmaceuticals

  • Vertex Pharmaceuticals Incorporated faces significant revenue concentration risk, as 96% of its product sales come from treatments for cystic fibrosis, making the company highly dependent on the performance of a single disease area and vulnerable to any competitive or regulatory challenges in that specific market.
  • Analysts at Erste Group Bank recently lowered their earnings estimates for the company, reducing their FY2026 EPS forecast from $16.68 to $16.65 and their FY2027 forecast from $19.09 to $18.97, which suggests that some financial experts are becoming more cautious about the company's ability to meet its growth targets in the near term.
  • The company's stock price has declined from its 52-week high of $560.25 to the current level of $523.93, indicating a recent downward trend that may reflect investor concerns about the company's valuation or the pace of its expansion into new therapeutic areas such as kidney disease.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$132.98 billion
P/E Ratio
30.50
Consensus Rating
Moderate Buy
Consensus Price Target
$579.81 (+10.7% Upside)
Volume
832,574 shares
Average Volume
1.23 million shares
Today's Range
$522.91
▼
$533.08
50-Day Range
$485.22
▼
$557.96
52-Week Range
$403.16
▼
$560.25
Dividend Yield
N/A
Bristol Myers Squibb stock logo

17. Bristol Myers Squibb NYSE:BMY

$61.58 -1.42 (-2.26%)
Closing price 10/23/2026 03:59 PM Eastern
Extended Trading
$61.71 +0.13 (+0.21%)
As of 10/23/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. More about Bristol Myers Squibb

Pros of Bristol Myers Squibb

  • Bristol-Myers Squibb recently reported that its drug izalontamab brengitecan reduced the risk of disease progression or death by 59% compared to chemotherapy in a Phase 3 trial for advanced breast cancer, a significant clinical success that strengthens the company's oncology pipeline and supports future regulatory filings.
  • The company expanded its multi-year collaboration with Tempus AI to license multimodal oncology data through 2031 and is collaborating with Pathos AI on AI-driven research for Alzheimer's disease, moves that are expected to improve research productivity and pipeline potential for investors.
  • Bristol-Myers Squibb offers an attractive dividend yield of 4.00%, providing a steady income stream for investors, while the stock currently trades at $61.58, which is below the average analyst price target of $64.88, suggesting potential for capital appreciation.

Cons of Bristol Myers Squibb

  • Bristol-Myers Squibb disclosed a patient death in an early-stage cell therapy study for multiple sclerosis, which introduces a safety overhang that may overshadow positive efficacy data and raise concerns about the risk profile of its pipeline.
  • Zacks Research recently downgraded Bristol-Myers Squibb from a "strong-buy" rating to a "hold" rating, reflecting a more cautious outlook from analysts who are concerned about the company's future growth trajectory.
  • Pre-earnings coverage anticipates a year-over-year decline in third-quarter earnings, with investors focused on the erosion of legacy drugs and the company's relatively high debt load, which could outweigh its inexpensive valuation in the near term.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$125.59 billion
P/E Ratio
13.56
Consensus Rating
Hold
Consensus Price Target
$64.88 (+5.4% Upside)
Volume
9.76 million shares
Average Volume
13.42 million shares
Today's Range
$61.31
▼
$62.84
50-Day Range
$56.73
▼
$68.06
52-Week Range
$42.52
▼
$68.64
Dividend Yield
4.00%
Medtronic stock logo

18. Medtronic NYSE:MDT

$95.48 -1.11 (-1.15%)
Closing price 10/23/2026 03:59 PM Eastern
Extended Trading
$95.55 +0.07 (+0.07%)
As of 10/23/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. More about Medtronic

Pros of Medtronic

  • Medtronic plc recently completed the separation of its MiniMed business, a strategic move that simplifies the company's portfolio and allows it to focus on its core medical technology strengths, which is a significant recent development for the stock.
  • The company secured CE Mark approval for its next-generation Vitalis portfolio of conduction system pacemakers, a product innovation that directly stimulates the heart's natural electrical wiring and positions Medtronic plc competitively in the cardiac care market.
  • Medtronic plc reported strong third-quarter earnings with revenue of $9.76 billion, beating analyst estimates of $9.55 billion, and EPS of $1.45, which exceeded the consensus of $1.39, demonstrating robust financial performance and operational efficiency.

Cons of Medtronic

  • Short interest in Medtronic plc has increased significantly, with shares shorted rising to 39,974,230 as of September 30, 2026, representing a 1.32% month-to-month increase and a short percentage of float of 3.13%, indicating growing bearish sentiment among traders.
  • Recent insider activity shows a trend of selling, with CEO Geoffrey Martha selling 50,000 shares and EVP Michael Marinaro selling 10,420 shares in October 2026, which may signal a lack of confidence in the stock's near-term performance from company leadership.
  • Medtronic plc experienced a net ETF selling of $94.9 million on October 16, 2026, suggesting that institutional investors and exchange-traded funds are reducing their exposure to the stock, which can put downward pressure on the share price.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$122.04 billion
P/E Ratio
23.52
Consensus Rating
Moderate Buy
Consensus Price Target
$102.88 (+7.7% Upside)
Volume
6.01 million shares
Average Volume
34.63 million shares
Today's Range
$95.38
▼
$96.89
50-Day Range
$85.51
▼
$96.48
52-Week Range
$73.31
▼
$106.33
Dividend Yield
2.98%
CVS Health stock logo

19. CVS Health NYSE:CVS

$93.54 -0.94 (-0.99%)
Closing price 10/23/2026 03:59 PM Eastern
Extended Trading
$93.61 +0.06 (+0.07%)
As of 10/23/2026 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. More about CVS Health

Pros of CVS Health

  • CVS Health Co. recently reported a significant earnings beat, posting $2.58 in earnings per share for the quarter compared to the consensus estimate of $1.87, which demonstrates strong operational performance and profitability that may drive investor confidence.
  • The company is actively targeting customers displaced by the closure of 1,000 Walgreens and Rite Aid stores, a strategic move that could increase prescription volume, retail sales, and customer retention for CVS Health Co. as it captures market share from exiting competitors.
  • CVS Health Co. has raised its full-year 2026 earnings per share guidance to a range of $7.90 to $8.10, exceeding the previous consensus estimate of $7.44, signaling management's confidence in the company's ability to deliver higher profits than initially expected by analysts.

Cons of CVS Health

  • Despite the earnings beat, CVS Health Co. stock closed at $93.62, down from a previous close of $94.75, indicating recent price weakness and potential market skepticism about the sustainability of the company's turnaround narrative.
  • Industry coverage highlights pressure from rising medical costs across managed care and uncertainty surrounding Medicare Advantage plan availability, which could limit valuation expansion and squeeze margins for CVS Health Co. despite improved earnings guidance.
  • CVS Health Co. faces leadership uncertainty in its technology division as Chief Information Officer Amaresh Siva is leaving to become Alaska Airlines' chief information technology officer, which may create near-term execution risks for the company's technology and AI initiatives.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$119.55 billion
P/E Ratio
24.75
Consensus Rating
Moderate Buy
Consensus Price Target
$107.80 (+15.2% Upside)
Volume
4.60 million shares
Average Volume
9.30 million shares
Today's Range
$93.22
▼
$94.40
50-Day Range
$84.96
▼
$97.36
52-Week Range
$69.51
▼
$110.68
Dividend Yield
2.82%
Stryker stock logo

20. Stryker NYSE:SYK

$307.65 +0.57 (+0.19%)
Closing price 10/23/2026 03:59 PM Eastern
Extended Trading
$306.28 -1.37 (-0.45%)
As of 10/23/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. More about Stryker

Pros of Stryker

  • Stryker Co. recently secured FDA clearance for its Sonopet 3 surgical navigation system, a development that promises to enhance surgical precision and efficiency for healthcare providers, with a full commercial launch expected later this fall which could drive future revenue growth.
  • The company demonstrated strong financial performance in its most recent quarterly report, beating consensus estimates with an EPS of $3.69 compared to the expected $3.49, while also achieving revenue of $6.59 billion, which exceeded analyst projections and indicated a 9.4% year-over-year increase in sales.
  • With a current stock price of $307.65, Stryker Co. trades at a significant discount to the consensus analyst price target of $370.68, suggesting substantial upside potential for investors as the stock remains well below its 52-week high of $389.33.

Cons of Stryker

  • Recent insider activity has been predominantly negative, with insiders selling 351,267 shares worth approximately $118.2 million over the last ninety days, including significant sales by Director Ronda E. Stryker and other executives, which may signal a lack of confidence in the stock's near-term trajectory.
  • Several prominent financial institutions have recently lowered their price targets or downgraded their ratings, such as Truist Financial cutting its target to $310.00 and Wolfe Research downgrading the stock to "peer perform," reflecting growing concerns about the company's valuation or growth outlook.
  • Stryker Co. experienced a significant earnings miss in the first quarter of 2026, reporting an EPS of $2.60 against a consensus estimate of $2.98 and revenue of $6.02 billion compared to the expected $6.34 billion, indicating potential challenges in maintaining consistent growth momentum.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$117.81 billion
P/E Ratio
31.88
Consensus Rating
Moderate Buy
Consensus Price Target
$369.00 (+19.9% Upside)
Volume
1.98 million shares
Average Volume
2.58 million shares
Today's Range
$305.00
▼
$309.57
50-Day Range
$269.98
▼
$340.20
52-Week Range
$267.00
▼
$389.33
Dividend Yield
1.15%
McKesson stock logo

21. McKesson NYSE:MCK

$1,000.53 -11.81 (-1.17%)
Closing price 10/23/2026 03:59 PM Eastern
Extended Trading
$995.82 -4.71 (-0.47%)
As of 10/23/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. More about McKesson

Pros of McKesson

  • McKesson Co. recently reported quarterly earnings that exceeded analyst expectations, with actual earnings per share of $9.93 compared to a consensus estimate of $9.56, demonstrating strong operational performance and profitability that supports the stock's recent momentum.
  • The stock is currently trading at $1,014.79, which is near its 52-week high of $1,030.27, indicating strong investor confidence and upward price momentum as the company continues to outperform the broader market.
  • Analysts have recently raised their price targets for the stock, with UBS increasing its target to $1,200 and Mizuho raising its target to $1,020, reflecting a bullish outlook on the company's future growth potential and valuation.

Cons of McKesson

  • Insiders have been selling shares of the company, with CEO Brian S Tyler selling 8,463 shares in July 2026 and EVP Francisco Fraga selling 800 shares in October 2026, which may indicate a lack of confidence from company leadership in the stock's near-term performance.
  • The company has a high payout ratio of 9.0%, which means it is using a significant portion of its earnings to pay dividends, potentially limiting its ability to reinvest in growth initiatives or manage cash flow during economic downturns.
  • McKesson Co. has a negative return on equity of 253.21%, which suggests that the company is not efficiently using its equity to generate profits, a metric that investors typically view as a warning sign for financial health.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$116.68 billion
P/E Ratio
26.77
Consensus Rating
Moderate Buy
Consensus Price Target
$997.12 (-0.3% Downside)
Volume
628,967 shares
Average Volume
699,605 shares
Today's Range
$997.02
▼
$1,012.50
50-Day Range
$841.21
▼
$1,029.52
52-Week Range
$723.68
▼
$1,030.27
Dividend Yield
0.38%
GSK stock logo

22. GSK NYSE:GSK

$50.74 -0.47 (-0.91%)
Closing price 10/23/2026 03:59 PM Eastern
Extended Trading
$50.74 0.00 (0.00%)
As of 10/23/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. More about GSK

Pros of GSK

  • GSK plc recently received FDA approval for Hibsago, the first functional cure for chronic hepatitis B, which allows patients to stop long-term treatment and supports a sales forecast of £2.2 billion, signaling a major breakthrough in the company's specialty medicine portfolio.
  • The company's immunotherapy drug Jemperli received accelerated FDA approval for treating advanced rectal cancer and locally advanced renal cancer, expanding its oncology footprint and providing new revenue streams in high-growth therapeutic areas.
  • GSK plc offers a dividend yield of 3.54% with a recent increase in its quarterly dividend to $0.4515, providing a reliable income stream for investors despite the stock trading at a current price of $50.75.

Cons of GSK

  • GSK plc is facing a $2.2 billion legal charge related to a Zantac settlement, which will significantly impact its near-term earnings and cash flow, creating financial headwinds for the company.
  • The company has experienced R&D setbacks, including a failed cough drug, which raises concerns about the efficiency of its research and development spending and the risk of further pipeline failures.
  • There is a looming patent cliff on GSK plc's biggest HIV medicine, which could lead to a significant loss of revenue as generic competitors enter the market, pressuring the company's overall financial performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$102.65 billion
P/E Ratio
15.87
Consensus Rating
Hold
Consensus Price Target
$55.33 (+9.0% Upside)
Volume
3.18 million shares
Average Volume
5.82 million shares
Today's Range
$50.29
▼
$50.92
50-Day Range
$46.24
▼
$52.92
52-Week Range
$42.85
▼
$61.69
Dividend Yield
3.49%
HCA Healthcare stock logo

23. HCA Healthcare NYSE:HCA

$469.45 +2.14 (+0.46%)
Closing price 10/23/2026 03:59 PM Eastern
Extended Trading
$466.02 -3.43 (-0.73%)
As of 10/23/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. More about HCA Healthcare

Pros of HCA Healthcare

  • HCA Healthcare, Inc. is currently trading at $459.14, which is below the consensus price target of $467.61 set by analysts, suggesting potential for near-term price appreciation as the stock aligns with Wall Street's valuation expectations.
  • The company demonstrated strong operational performance in its most recent quarterly report, beating consensus estimates with earnings per share of $7.59 against an expected $7.56, while also exceeding revenue forecasts with $20.23 billion in sales compared to the $19.76 billion consensus, indicating robust demand for its healthcare services.
  • Analysts maintain a "Moderate Buy" consensus rating for the stock, with sixteen investment analysts assigning a Buy rating and only one assigning a Sell rating, reflecting broad institutional confidence in the company's long-term growth trajectory and market position.

Cons of HCA Healthcare

  • Legal and regulatory risks are emerging, as the company is currently disputing a state's authority to enforce a purchase agreement from seven years ago, and a law firm is investigating claims on behalf of investors, which could lead to potential liabilities or distractions for management.
  • Short interest in the stock has been increasing, with shares shorted rising to 4,884,718 in the most recent reporting period, indicating that a significant portion of the market is betting against the stock's performance, which can create downward pressure on the share price.
  • Recent insider activity shows a trend of selling, with several executives, including EVP Michael R. McAlevey and SVP Jennifer Berres, selling shares in early 2026, which may signal a lack of confidence in the stock's near-term upside from those closest to the company's operations.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$101.55 billion
P/E Ratio
15.72
Consensus Rating
Moderate Buy
Consensus Price Target
$467.61 (-0.4% Downside)
Volume
1.03 million shares
Average Volume
1.08 million shares
Today's Range
$461.77
▼
$473.46
50-Day Range
$401.80
▼
$470.25
52-Week Range
$353.99
▼
$556.52
Dividend Yield
0.67%
Sanofi stock logo

24. Sanofi NASDAQ:SNY

$41.60 -0.36 (-0.86%)
Closing price 10/23/2026 04:00 PM Eastern
Extended Trading
$41.53 -0.07 (-0.17%)
As of 10/23/2026 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. More about Sanofi

Pros of Sanofi

  • Sanofi recently announced a worldwide strategic collaboration with ScionxBio to develop and commercialize extended exposure long-acting xRNA therapeutics, signaling a significant expansion into next-generation mRNA technologies that could drive future growth.
  • The company broke ground on a new state-of-the-art insulin manufacturing facility at its BioCampus in Frankfurt, Germany, which demonstrates a strong commitment to scaling production in a key therapeutic area and securing supply chain capabilities.
  • Sanofi signed a letter of intent with the Canadian Drug Alliance for Dupixent in four additional indications, indicating continued expansion of its flagship biologic's market reach and potential for increased revenue from this high-growth product.

Cons of Sanofi

  • Sanofi recently hit a new 52-week low of $39.18, indicating significant downward price momentum and potential investor concern about the company's near-term performance or valuation.
  • The consensus recommendation from 21 analysts is "Hold," with 12 analysts issuing a hold rating and only 8 issuing buy or strong buy ratings, suggesting that the market sees limited immediate upside potential relative to the current price.
  • Short interest in Sanofi has increased over the past few months, with shares shorted rising to 10.6 million as of September 30, 2026, indicating that a growing number of investors are betting against the stock's price appreciation.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$100.86 billion
P/E Ratio
21.78
Consensus Rating
Hold
Consensus Price Target
$49.50 (+19.0% Upside)
Volume
2.01 million shares
Average Volume
3.66 million shares
Today's Range
$41.33
▼
$41.75
50-Day Range
$39.12
▼
$46.02
52-Week Range
$39.07
▼
$52.68
Dividend Yield
4.24%
Elevance Health stock logo

25. Elevance Health NYSE:ELV

$440.05 -5.23 (-1.17%)
Closing price 10/23/2026 03:59 PM Eastern
Extended Trading
$440.90 +0.84 (+0.19%)
As of 10/23/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. The company operates in the pharmacy services business; and markets and offers pharmacy services, including pharmacy benefit management, as well as home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services. In addition, it provides healthcare-related services and capabilities, including utilization management, behavioral health, integrated care delivery, palliative care, payment integrity services, subrogation services, and health and wellness programs, as well as services related to data management, information technology, and business operations. Further, the company is involved in the National Government Services business. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brand names. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is headquartered in Indianapolis, Indiana.

Market Capitalization
$95.05 billion
P/E Ratio
18.77
Consensus Rating
Moderate Buy
Consensus Price Target
$455.57 (+3.5% Upside)
Volume
1.17 million shares
Average Volume
1.33 million shares
Today's Range
$439.00
▼
$445.42
50-Day Range
$381.68
▼
$445.85
52-Week Range
$274.84
▼
$450.69
Dividend Yield
1.56%
Regeneron Pharmaceuticals stock logo

26. Regeneron Pharmaceuticals NASDAQ:REGN

$805.02 -14.07 (-1.72%)
Closing price 10/23/2026 04:00 PM Eastern
Extended Trading
$805.50 +0.48 (+0.06%)
As of 10/23/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. More about Regeneron Pharmaceuticals

Pros of Regeneron Pharmaceuticals

  • Regeneron Pharmaceuticals, Inc. recently reported strong financial performance in its most recent quarter, with revenue of $4.29 billion, which exceeded analyst expectations of $3.82 billion and represented a 16.7% year-over-year increase, driven primarily by the strong performance of its Dupixent product.
  • The company demonstrated significant earnings power by reporting an EPS of $14.29 for the quarter, which topped the consensus estimate of $10.16 by $4.13, indicating that the business is generating substantial profit relative to its share count and outperforming market expectations.
  • Regeneron Pharmaceuticals, Inc. has received positive momentum from institutional investors, with Vest Financial LLC increasing its stake by 59.3% in the third quarter and Cantor Fitzgerald Investment Advisors L.P. purchasing a new position of 24,900 shares, suggesting growing confidence in the company's long-term value.

Cons of Regeneron Pharmaceuticals

  • Corporate insiders have been selling shares recently, with Andrew J. Murphy selling 4,147 shares at an average price of $772.70 and Marion Mccourt selling 1,215 shares at $850.00, which may signal that company executives are taking profits or reducing their personal exposure to the stock.
  • Some large institutional investors have reduced their positions, such as Robeco Institutional Asset Management B.V., which decreased its stake by 12.5% in the third quarter, and Assenagon Asset Management S.A., which cut its position by 84.9%, indicating that some major holders are exiting or trimming their investments.
  • The stock is trading at a P/E ratio of 20.24, which is a valuation metric comparing the stock price to earnings per share, and while this is not excessively high, it may limit the upside potential compared to growth stocks with lower valuations, especially if earnings growth slows.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$82.88 billion
P/E Ratio
19.90
Consensus Rating
Moderate Buy
Consensus Price Target
$846.28 (+5.1% Upside)
Volume
527,731 shares
Average Volume
705,231 shares
Today's Range
$801.22
▼
$819.09
50-Day Range
$726.47
▼
$852.03
52-Week Range
$575.93
▼
$859.34
Dividend Yield
0.46%
Cigna Group stock logo

27. Cigna Group NYSE:CI

$306.93 -8.95 (-2.83%)
Closing price 10/23/2026 03:59 PM Eastern
Extended Trading
$307.24 +0.31 (+0.10%)
As of 10/23/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. More about Cigna Group

Pros of Cigna Group

  • The stock recently reached a new 52-week high of $316.27, with the current price trading at $306.93, indicating strong recent momentum and investor confidence in the company's performance.
  • Analysts maintain a consensus rating of Moderate Buy with a price target of $338.24, suggesting that the current market price of $306.93 offers potential upside of over 10% based on professional forecasts.
  • The company demonstrated strong financial performance in the most recent quarter, reporting earnings per share of $7.78 which exceeded the consensus estimate of $7.60, while revenue grew 6.7% year-over-year to $71.56 billion.

Cons of Cigna Group

  • Insiders have been net sellers recently, with executives like Nicole Jones and Everett Neville selling thousands of shares in August and September 2026, which can signal a lack of confidence in near-term stock appreciation.
  • The company has a current ratio of 0.76, which is below 1.0, indicating that its current liabilities exceed its current assets, potentially raising concerns about short-term liquidity and debt management.
  • Short interest has been increasing, with shares shorted rising to 6,951,241 as of September 30, 2026, suggesting that a growing number of traders are betting against the stock's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$81.11 billion
P/E Ratio
12.70
Consensus Rating
Moderate Buy
Consensus Price Target
$338.24 (+10.2% Upside)
Volume
1.78 million shares
Average Volume
1.61 million shares
Today's Range
$305.51
▼
$315.86
50-Day Range
$265.54
▼
$315.01
52-Week Range
$239.51
▼
$316.27
Dividend Yield
2.03%
Moderna stock logo

28. Moderna NASDAQ:MRNA

$200.10 -2.53 (-1.25%)
Closing price 10/23/2026 04:00 PM Eastern
Extended Trading
$201.35 +1.25 (+0.62%)
As of 10/23/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. More about Moderna

Pros of Moderna

  • Moderna, Inc. demonstrated significant clinical success with its personalized cancer vaccine, intismeran autogene, which, when combined with Merck's Keytruda, showed a 42% reduction in the risk of melanoma recurrence or death in Phase 3 trials, marking a major advancement in immuno-oncology treatment.
  • The company's stock price is currently trading at $200.10, which is significantly above its 52-week low of $22.28, reflecting a substantial recovery and strong market confidence in the company's pivot toward oncology and other therapeutic areas beyond its initial pandemic-era products.
  • Moderna, Inc. has shown strong revenue growth, with the most recent quarter reporting $145.00 million in revenue, which beat analyst expectations of $102.93 million, indicating that the company's commercial pipeline is gaining traction and generating higher-than-anticipated cash flow.

Cons of Moderna

  • The company is currently unprofitable, with a negative P/E ratio of -25.04 and a reported EPS of ($1.97) for the most recent quarter, indicating that it is still burning cash and has not yet achieved sustainable profitability despite its revenue growth.
  • Wall Street analysts have a mixed outlook, with a consensus rating of "Hold" and an average price target of $103.95, which is significantly lower than the current stock price of $200.10, suggesting that many institutional investors believe the stock is overvalued relative to its fundamental earnings potential.
  • Recent insider activity shows a trend of selling, with President Stephen Hoge and CFO Jamey Mock both selling significant portions of their holdings in September and October 2026, which may signal a lack of confidence from company leadership in the current stock valuation.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$79.89 billion
P/E Ratio
N/A
Consensus Rating
Hold
Consensus Price Target
$103.95 (-48.1% Downside)
Volume
21.51 million shares
Average Volume
19.46 million shares
Today's Range
$183.00
▼
$206.97
50-Day Range
$62.96
▼
$245.81
52-Week Range
$22.28
▼
$254.48
Dividend Yield
N/A
Boston Scientific stock logo

29. Boston Scientific NYSE:BSX

$45.67 -0.34 (-0.74%)
Closing price 10/23/2026 03:59 PM Eastern
Extended Trading
$45.63 -0.04 (-0.09%)
As of 10/23/2026 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. More about Boston Scientific

Pros of Boston Scientific

  • The stock is currently trading at $44.49, which is near its 52-week low of $41.38, offering a potential entry point for value-oriented investors. This price represents a significant discount to the consensus price target of $70.19, suggesting substantial upside potential if the company meets its performance expectations.
  • Boston Scientific Co. has demonstrated consistent earnings beats recently, reporting $0.86 per share in the most recent quarter against a consensus estimate of $0.83. This ability to exceed analyst expectations, combined with a year-over-year revenue growth of 7.5%, indicates strong operational execution and demand for its medical devices.
  • The company maintains a favorable valuation profile with a P/E ratio of 18.01, which is reasonable for a healthcare equipment leader. Additionally, the low beta of 0.58 suggests that the stock is less volatile than the broader market, potentially providing a more stable investment experience during periods of market uncertainty.

Cons of Boston Scientific

  • The stock has experienced a significant decline from its 52-week high of $105.65 to the current price of $44.49, indicating a downward trend that may continue. This drop of over 50% from peak levels suggests that investors are concerned about the company's future growth trajectory or market conditions.
  • Boston Scientific Co. recently recalled 262,686 catheters due to a life-threatening tip failure risk. Such product safety issues can lead to regulatory scrutiny, potential legal liabilities, and damage to the company's reputation, which may impact future sales and customer trust.
  • The company's guidance for Q3 2026 EPS of $0.800-$0.820 is below the consensus estimate of $0.840, suggesting that management expects weaker performance than analysts anticipate. This gap between internal guidance and external expectations could lead to a negative market reaction when earnings are released.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$66.22 billion
P/E Ratio
18.49
Consensus Rating
Moderate Buy
Consensus Price Target
$68.23 (+49.4% Upside)
Volume
8.77 million shares
Average Volume
15.84 million shares
Today's Range
$45.22
▼
$46.16
50-Day Range
$41.55
▼
$52.02
52-Week Range
$41.38
▼
$105.65
Dividend Yield
N/A
Takeda Pharmaceutical stock logo

30. Takeda Pharmaceutical NYSE:TAK

$20.26 -0.11 (-0.52%)
Closing price 10/23/2026 03:59 PM Eastern
Extended Trading
$20.24 -0.01 (-0.05%)
As of 10/23/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. More about Takeda Pharmaceutical

Pros of Takeda Pharmaceutical

  • Takeda Pharmaceutical Company Limited recently announced positive results from the Phase 3 G-HOPE-001 study of arcotatug tavatecan in advanced gastric cancer, where the drug met dual endpoints and extended survival, signaling a significant potential new revenue driver in the oncology space.
  • The company launched ORZEYFUL (oveporexton) in Japan and China for the treatment of narcolepsy type 1, representing a first-in-class orexin receptor 2 agonist that addresses a significant unmet medical need and expands the company's neuroscience portfolio.
  • New data from the VERDICT trial demonstrated that treating ulcerative colitis patients with ENTYVIO to achieve disease clearance significantly reduced the risk of disease-related complications by nearly 70 percent, reinforcing the long-term value and clinical superiority of this flagship gastroenterology product.

Cons of Takeda Pharmaceutical

  • The stock currently trades at a price-to-earnings ratio of 59.57, which is significantly higher than typical pharmaceutical industry averages, suggesting that the current valuation may be stretched relative to its earnings power.
  • Insider selling has been notable, with insiders selling a total of 627,457 shares valued at approximately $10.98 million in the last three months, including sales by CEO Julie Kim and other executives, which can signal a lack of confidence or a desire to diversify personal holdings.
  • The company's quick ratio is 0.62, which is below 1.0, indicating that Takeda Pharmaceutical Company Limited may face challenges in covering its short-term liabilities with its most liquid assets, potentially impacting financial flexibility.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$64.85 billion
P/E Ratio
59.57
Consensus Rating
Moderate Buy
Consensus Price Target
N/A
Volume
2.10 million shares
Average Volume
2.81 million shares
Today's Range
$20.17
▼
$20.39
50-Day Range
$17.39
▼
$20.37
52-Week Range
$12.99
▼
$20.39
Dividend Yield
2.38%
Cencora stock logo

31. Cencora NYSE:COR

$330.77 -7.71 (-2.28%)
Closing price 10/23/2026 03:59 PM Eastern
Extended Trading
$330.56 -0.20 (-0.06%)
As of 10/23/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. More about Cencora

Pros of Cencora

  • Cencora, Inc. recently announced a definitive agreement to acquire the remaining 96% stake in American Oncology Network for approximately $2.4 billion, a strategic move that adds about 350 physicians to its network and strengthens its support for community oncology practices, potentially expanding its provider network and oncology-related revenue opportunities.
  • Analyst sentiment remains positive with recent price target increases, such as Robert W. Baird raising its target to $375.00 and Argus lifting its target to $380.00, both maintaining buy or outperform ratings, which signals confidence in the company's growth prospects and suggests potential upside from the current stock price of $330.77.
  • The company demonstrated strong financial performance in its most recent quarterly earnings report, beating analysts' consensus estimates with earnings per share of $4.48 compared to the expected $4.35, while also reporting revenue of $84.75 billion, which exceeded the consensus estimate of $84.31 billion and represented a 5.1% year-over-year increase.

Cons of Cencora

  • The $2.4 billion acquisition of American Oncology Network, while strategically attractive, introduces risks related to the purchase price, financing, and integration costs, and investors will need to assess the company's ability to generate sufficient returns from the expanded physician platform to justify the investment.
  • Some analysts have taken a more cautious stance, with UBS lowering its price target to $400, which, although still above the current trading level, creates a counterpoint to the more bullish revisions from other firms and suggests potential limitations in the stock's near-term upside.
  • Insider selling activity has been notable, with EVP Elizabeth Campbell selling 11,300 shares in August 2026 and CEO Robert P. Mauch selling 5,096 shares in January 2026, which may signal that company executives are taking advantage of higher stock prices to reduce their personal holdings.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$63.16 billion
P/E Ratio
24.57
Consensus Rating
Moderate Buy
Consensus Price Target
$366.44 (+10.8% Upside)
Volume
1.17 million shares
Average Volume
1.25 million shares
Today's Range
$330.31
▼
$338.07
50-Day Range
$300.71
▼
$343.40
52-Week Range
$244.82
▼
$377.54
Dividend Yield
0.71%
Natera stock logo

32. Natera NASDAQ:NTRA

$403.95 +2.58 (+0.64%)
Closing price 10/23/2026 04:00 PM Eastern
Extended Trading
$405.96 +2.01 (+0.50%)
As of 10/23/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

Market Capitalization
$58.23 billion
P/E Ratio
N/A
Consensus Rating
Moderate Buy
Consensus Price Target
$379.20 (-6.1% Downside)
Volume
1.10 million shares
Average Volume
1.65 million shares
Today's Range
$395.33
▼
$408.28
50-Day Range
$311.69
▼
$425.64
52-Week Range
$181.00
▼
$437.41
Dividend Yield
N/A
Cardinal Health stock logo

33. Cardinal Health NYSE:CAH

$249.47 -6.17 (-2.41%)
Closing price 10/23/2026 03:59 PM Eastern
Extended Trading
$251.40 +1.93 (+0.77%)
As of 10/23/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cardinal Health, Inc operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. More about Cardinal Health

Pros of Cardinal Health

  • Cardinal Health, Inc. recently reached a new 52-week high of $259.09, with the current stock price trading at $257.50, reflecting strong market momentum and investor confidence in the company's recent performance.
  • The company demonstrated strong earnings momentum by beating consensus estimates in its most recent quarterly report, posting earnings per share of $2.91 against an expected $2.42, which signals effective cost management and operational efficiency.
  • Analyst sentiment remains positive with a consensus rating of Moderate Buy and a target price of $269.38, indicating that financial experts believe the stock has approximately 4.6% upside potential from its current level.

Cons of Cardinal Health

  • Despite the earnings beat, the company reported revenue of $63.67 billion in its latest quarter, which fell short of the analyst consensus estimate of $65.15 billion, suggesting potential challenges in top-line growth or demand.
  • Cardinal Health, Inc. reported a negative return on equity of 98.53% in its most recent quarter, a metric that indicates the company is not generating positive returns on the equity invested by shareholders, which can be a concern for long-term value creation.
  • Corporate insiders have been selling shares, with CEO Jason M. Hollar selling 80,000 shares and CEO Deborah Weitzman selling 7,354 shares in August 2026, which may signal a lack of confidence in the stock's near-term upside from those closest to the company.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$57.79 billion
P/E Ratio
34.50
Consensus Rating
Moderate Buy
Consensus Price Target
$269.38 (+8.0% Upside)
Volume
1.67 million shares
Average Volume
1.72 million shares
Today's Range
$249.24
▼
$255.64
50-Day Range
$220.12
▼
$257.50
52-Week Range
$158.70
▼
$259.21
Dividend Yield
0.81%
argenex stock logo

34. argenex NASDAQ:ARGX

$873.71 -2.05 (-0.23%)
Closing price 10/23/2026 04:00 PM Eastern
Extended Trading
$871.02 -2.70 (-0.31%)
As of 10/23/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. More about argenex

Pros of argenex

  • argenx SE recently reported strong third-quarter financial results, posting earnings per share of $7.32, which significantly exceeded the analyst consensus estimate of $5.86, demonstrating robust profitability and operational efficiency that supports the current stock price of $890.05.
  • The company's lead product, VYVGART, continues to drive substantial revenue growth, with the most recent quarter generating $1.54 billion in revenue compared to the expected $1.45 billion, highlighting the strong market demand for its therapies targeting severe autoimmune diseases like generalized myasthenia gravis.
  • Wall Street maintains a positive outlook on the stock, with a consensus rating of "Moderate Buy" and a consensus price target of $1,158.61, suggesting significant potential upside from the current trading levels as analysts like Wells Fargo and BNP Paribas Exane have recently issued "overweight" and "outperform" ratings.

Cons of argenex

  • Several major financial institutions have recently lowered their price targets, with Royal Bank Of Canada cutting its target from $1,100.00 to $1,025.00 and Oppenheimer reducing its target from $1,100.00 to $1,038.00, suggesting that some analysts believe the stock may be overvalued relative to its current growth rate.
  • The stock has experienced significant volatility and recent price declines, including a gap down of approximately $97.21 on October 8, 2026, and trading well below its 52-week high of $1,072.75, which may indicate short-term market uncertainty or profit-taking by investors.
  • Legal risks remain a concern for shareholders, as indicated by recent reports of a fraud investigation involving argenx SE, where investors with significant losses are being encouraged to join a class action lawsuit, which could lead to potential financial liabilities and reputational damage for the company.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$54.94 billion
P/E Ratio
30.49
Consensus Rating
Moderate Buy
Consensus Price Target
$1,142.37 (+30.7% Upside)
Volume
295,822 shares
Average Volume
509,396 shares
Today's Range
$865.72
▼
$887.07
50-Day Range
$802.64
▼
$1,058.90
52-Week Range
$661.85
▼
$1,072.75
Dividend Yield
N/A
Becton, Dickinson and Company stock logo

35. Becton, Dickinson and Company NYSE:BDX

$198.96 -1.46 (-0.73%)
Closing price 10/23/2026 03:59 PM Eastern
Extended Trading
$202.22 +3.26 (+1.64%)
As of 10/23/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. More about Becton, Dickinson and Company

Pros of Becton, Dickinson and Company

  • Recent analyst sentiment has shifted positively, with Zacks Research upgrading the stock from a hold to a strong-buy rating on October 23, 2026, and Wolfe Research initiating coverage with an outperform rating on October 20, 2026, suggesting that institutional investors are increasingly confident in the company's future performance.
  • The stock is currently trading at $198.96, which is near its 52-week high of $200.47, indicating strong momentum and market confidence in the company's ability to deliver value, especially given that the stock has gained 25.5% in the last six months.
  • Becton, Dickinson and Company demonstrated strong financial performance in its most recent quarter, reporting earnings per share of $3.23, which exceeded the consensus estimate of $3.14, and revenue of $4.98 billion, surpassing the expected $4.89 billion, with a year-over-year revenue growth of 5.4%.

Cons of Becton, Dickinson and Company

  • The consensus price target from analysts is $185.07, which is below the current stock price of $198.96, suggesting that the stock may be overvalued relative to what analysts believe it is worth, and there is limited upside potential if the stock reverts to the consensus target.
  • Insiders have been selling shares of the company, with executives such as Michael Feld and Roland Goette selling a total of 6,906 shares worth $1,265,855 in the last three months, which could indicate a lack of confidence in the company's near-term prospects or a desire to lock in gains.
  • The company's debt-to-equity ratio is 0.55, which, while not excessively high, indicates that the company has a moderate level of debt relative to its equity, and investors should be aware of the potential risks associated with leverage, especially in a rising interest rate environment.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$54.81 billion
P/E Ratio
59.93
Consensus Rating
Moderate Buy
Consensus Price Target
$185.07 (-7.0% Downside)
Volume
1.30 million shares
Average Volume
1.54 million shares
Today's Range
$197.15
▼
$200.42
50-Day Range
$176.18
▼
$200.21
52-Week Range
$127.59
▼
$200.47
Dividend Yield
2.10%
Veeva Systems stock logo

36. Veeva Systems NYSE:VEEV

$323.31 +0.76 (+0.24%)
Closing price 10/23/2026 03:59 PM Eastern
Extended Trading
$323.00 -0.31 (-0.10%)
As of 10/23/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States. More about Veeva Systems

Pros of Veeva Systems

  • Veeva Systems Inc. recently reported strong financial performance for the quarter ended August 26, 2026, beating analyst expectations with earnings per share of $2.35 compared to a consensus estimate of $2.23, while also exceeding revenue forecasts with $927.96 million in sales against an expected $905.38 million, demonstrating robust demand for its cloud software solutions in the life sciences industry.
  • The company has provided optimistic forward-looking guidance, projecting full-year 2027 earnings per share of $9.210 and quarterly revenue between $932.0 million and $935.0 million for the third quarter of 2027, which significantly exceeds the consensus estimates of $8.580 for annual EPS and $917.9 million for quarterly revenue, suggesting continued strong growth momentum.
  • Institutional investors are showing renewed confidence in the stock, with several major firms raising their price targets recently, including Barclays increasing its target to $360.00 and Baird adjusting its target to $350.00, reflecting a consensus rating of Moderate Buy and a collective belief in the company's long-term value proposition.

Cons of Veeva Systems

  • Insider selling activity has been notable recently, with executives such as SVP Jonathan Faddis selling 5,198 shares at an average price of $299.72 and EVP Daniel J. Rizzo selling 4,841 shares at $276.51, which can sometimes signal that company insiders believe the stock is overvalued or are looking to diversify their personal holdings.
  • The stock is trading at a premium valuation with a P/E ratio of 52.11, which is significantly higher than the broader market average, meaning investors are paying a high price for each dollar of earnings, and this can limit upside potential if the company fails to sustain its high growth rates.
  • Some institutional investors have reduced their positions in the company, such as Strategic Planning Group LLC decreasing its stake by 47.6% and Robeco Institutional Asset Management B.V. trimming its stake by 29.1% in the third quarter, which may indicate a lack of confidence in the stock's near-term performance from certain large holders.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$52.30 billion
P/E Ratio
53.18
Consensus Rating
Moderate Buy
Consensus Price Target
$287.79 (-11.0% Downside)
Volume
1.37 million shares
Average Volume
1.48 million shares
Today's Range
$319.00
▼
$324.76
50-Day Range
$238.40
▼
$323.31
52-Week Range
$148.05
▼
$325.99
Dividend Yield
N/A
Edwards Lifesciences stock logo

37. Edwards Lifesciences NYSE:EW

$89.15 -0.94 (-1.05%)
Closing price 10/23/2026 03:59 PM Eastern
Extended Trading
$89.16 +0.01 (+0.01%)
As of 10/23/2026 07:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. More about Edwards Lifesciences

Pros of Edwards Lifesciences

  • Edwards Lifesciences Co. recently secured FDA approval for its PASCAL Precision system for tricuspid valve repair, a development that positions the company as the only supplier in the U.S. offering both repair and replacement transcatheter options for these valves, significantly expanding its addressable market and competitive moat.
  • The company demonstrated strong financial performance in its most recent quarter, reporting earnings per share of $0.78 which exceeded the consensus estimate of $0.74, while revenue grew 13.6% year-over-year to $1.74 billion, indicating robust demand for its structural heart disease therapies.
  • Wall Street analysts maintain a positive outlook on the stock, with a consensus rating of Moderate Buy and an average price target of $100.27, which suggests approximately 12% upside potential from the current stock price of $89.15.

Cons of Edwards Lifesciences

  • The FDA issued a high-risk early alert regarding a recall of specific lots of the company's Commander M delivery systems due to reports of balloons bursting during procedures, which resulted in one patient death and a serious injury, posing significant regulatory and reputational risks.
  • Insider selling activity has been notable, with multiple executives including VP Daniel J. Lippis and VP Donald E. Bobo Jr. selling thousands of shares in recent months, which can signal a lack of confidence from those with the most intimate knowledge of the company's operations.
  • Several institutional investors have reduced their stakes in the company, with Robeco Institutional Asset Management B.V. decreasing its holdings by 13.0% and Investment House LLC cutting its position by 52.3% in the third quarter, suggesting that large funds are taking profits or reassessing their exposure.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$51.29 billion
P/E Ratio
51.23
Consensus Rating
Moderate Buy
Consensus Price Target
$100.27 (+12.5% Upside)
Volume
3.10 million shares
Average Volume
3.56 million shares
Today's Range
$88.97
▼
$91.05
50-Day Range
$84.18
▼
$92.36
52-Week Range
$74.66
▼
$96.29
Dividend Yield
N/A
Humana stock logo

38. Humana NYSE:HUM

$421.56 +0.60 (+0.14%)
Closing price 10/23/2026 03:59 PM Eastern
Extended Trading
$421.75 +0.19 (+0.04%)
As of 10/23/2026 07:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. More about Humana

Pros of Humana

  • Humana Inc. recently formed a joint venture with BlackRock to acquire a majority stake in its CenterWell senior primary care clinics for $2.8 billion, a move that injects significant capital into the business, eases balance sheet liabilities, and supports the expansion of its clinic network.
  • The company's stock is currently trading at $420.97, which is well above its 52-week low of $163.11 and reflects a strong upward momentum, as the stock has returned 112% over the last six months, significantly outperforming the broader market and the S&P 500.
  • Humana Inc. is expected to have 95% of its members in four-star plans for the upcoming period, a dramatic improvement from the previous 20%, which signals a major enhancement in service quality and member satisfaction that could drive future enrollment and retention.

Cons of Humana

  • Humana Inc. is discontinuing Medicare Advantage plans that will affect approximately 600,000 members, a significant reduction in its customer base that could lead to revenue loss and increased competition for remaining members from other insurers.
  • The stock is trading at a high price-to-earnings ratio of 39.83, which is significantly above the market average, suggesting that the stock may be overvalued relative to its current earnings, especially given the recent surge in price from its 52-week low.
  • Short interest in Humana Inc. has been increasing, with the number of shares shorted rising to 2,789,982 in the most recent reporting period, indicating that a growing number of investors are betting against the stock's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$50.68 billion
P/E Ratio
39.88
Consensus Rating
Moderate Buy
Consensus Price Target
$453.30 (+7.5% Upside)
Volume
1.20 million shares
Average Volume
1.76 million shares
Today's Range
$417.00
▼
$425.93
50-Day Range
$371.93
▼
$432.24
52-Week Range
$163.11
▼
$456.50
Dividend Yield
0.84%
Agilent Technologies stock logo

39. Agilent Technologies NYSE:A

$172.98 -0.91 (-0.52%)
Closing price 10/23/2026 03:59 PM Eastern
Extended Trading
$171.80 -1.18 (-0.68%)
As of 10/23/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. More about Agilent Technologies

Pros of Agilent Technologies

  • Agilent Technologies, Inc. recently announced the acquisition of Proscia, a digital pathology specialist, for an upfront payment of $240 million and up to $270 million in total, which expands the company's portfolio into AI-enabled digital pathology and strengthens its position in the diagnostics and genomics segment.
  • The company demonstrated strong financial performance in its most recent quarter, reporting earnings per share of $1.62, which beat analyst consensus estimates of $1.49 by $0.13, while also achieving revenue of $1.88 billion, exceeding the expected $1.84 billion and representing an 8.1% year-over-year increase.
  • Wall Street analysts have shown increasing confidence in the stock, with TD Cowen raising its price objective to $196.00 and Royal Bank of Canada lifting its target to $185.00, contributing to a consensus rating of Moderate Buy and a consensus price target of $173.65, which suggests potential upside from the current trading levels.

Cons of Agilent Technologies

  • The stock is trading at $172.98, which is very close to the consensus price target of $173.65, leaving limited room for further upside based on current analyst expectations, and the price is also near the 52-week high, which may indicate the stock is overextended in the short term.
  • Insider selling activity has been observed, with Director Mikael Dolsten selling 634 shares in September 2026 and CEO Padraig McDonnell selling shares in November 2025, which can be interpreted as a lack of confidence from company insiders or a desire to diversify personal holdings.
  • The company has a beta of 1.21, which is higher than the market average of 1.0, indicating that Agilent Technologies, Inc. is more volatile than the overall market and may experience larger price swings during periods of market turbulence.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$48.79 billion
P/E Ratio
34.05
Consensus Rating
Moderate Buy
Consensus Price Target
$181.00 (+4.6% Upside)
Volume
1.76 million shares
Average Volume
2.22 million shares
Today's Range
$169.89
▼
$173.59
50-Day Range
$143.12
▼
$177.93
52-Week Range
$108.35
▼
$179.10
Dividend Yield
0.59%
IQVIA stock logo

40. IQVIA NYSE:IQV

$279.47 +1.15 (+0.41%)
Closing price 10/23/2026 03:59 PM Eastern
Extended Trading
$274.81 -4.66 (-1.67%)
As of 10/23/2026 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. More about IQVIA

Pros of IQVIA

  • IQVIA Holdings Inc. recently reported strong second-quarter results with revenue of $4.37 billion, which exceeded the consensus estimate of $4.30 billion, and earnings per share of $3.15, beating the consensus estimate of $3.03, demonstrating the company's ability to outperform market expectations and drive shareholder value through operational efficiency and demand for its clinical research services.
  • The stock is currently trading at $279.47, which is near its 52-week high of $282.98, indicating strong momentum and investor confidence in the company's trajectory, as the share price has significantly outperformed its 52-week low of $154.50, reflecting a robust recovery and growth phase in the life sciences tools and services sector.
  • Analysts have shown increasing optimism, with the consensus rating standing at "Moderate Buy" and a recent average price target of $274.31, while several firms such as UBS Group and Royal Bank of Canada have issued "Buy" or "Outperform" ratings with price targets as high as $345.00, suggesting that the current valuation may still offer upside potential relative to institutional forecasts.

Cons of IQVIA

  • Insider selling activity has been notable, with insiders selling a total of 15,581 shares valued at approximately $3.8 million over the last three months, including significant sales by executives such as Eric Sherbet and Bhavik Patel, which may signal that company leadership is taking advantage of the recent stock price appreciation to reduce their personal exposure to the equity.
  • The company carries a high debt-to-equity ratio of 2.18, which indicates a significant level of leverage relative to its equity base, potentially increasing financial risk and limiting the company's flexibility to invest in growth initiatives or weather economic downturns, especially given the capital-intensive nature of the life sciences research industry.
  • Short interest has remained relatively elevated, with 3,216,119 shares shorted as of the most recent record date, representing approximately 1.99% of the float, and while this has decreased slightly from previous months, the persistent presence of short sellers suggests that a portion of the market remains skeptical about the sustainability of IQVIA's recent performance and valuation levels.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$45.98 billion
P/E Ratio
34.67
Consensus Rating
Moderate Buy
Consensus Price Target
$278.75 (-0.3% Downside)
Volume
981,209 shares
Average Volume
1.32 million shares
Today's Range
$274.67
▼
$279.58
50-Day Range
$240.25
▼
$279.47
52-Week Range
$154.50
▼
$282.98
Dividend Yield
N/A
Teva Pharmaceutical Industries stock logo

41. Teva Pharmaceutical Industries NYSE:TEVA

$39.39 -0.82 (-2.04%)
Closing price 10/23/2026 03:59 PM Eastern
Extended Trading
$39.42 +0.03 (+0.08%)
As of 10/23/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

Market Capitalization
$45.92 billion
P/E Ratio
65.65
Consensus Rating
Moderate Buy
Consensus Price Target
$46.08 (+17.0% Upside)
Volume
5.60 million shares
Average Volume
6.11 million shares
Today's Range
$39.11
▼
$39.84
50-Day Range
$36.03
▼
$41.44
52-Week Range
$18.88
▼
$42.02
Dividend Yield
N/A
Medline stock logo

42. Medline NASDAQ:MDLN

$34.09 -0.79 (-2.26%)
Closing price 10/23/2026 04:00 PM Eastern
Extended Trading
$34.01 -0.08 (-0.23%)
As of 10/23/2026 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Our mission is to make healthcare run better by delivering improved clinical, financial, and operational outcomes. We are the largest provider of medical-surgical (“med-surg”) products and supply chain solutions serving all points of care, based on total net sales of med-surg products. We deliver mission-critical products used daily across the full range of care settings, from hospitals and surgery centers to physician offices and post-acute facilities. Through our two segments, Medline Brand and Supply Chain Solutions, we offer approximately 335,000 med-surg products, including surgical and procedural kits, gloves and protective apparel, urological and incontinence care, wound care, and consumable lab and diagnostics products. We hold the leading position across several of our end markets and many of our key product families. We distribute these products through our expansive network of 69 global distribution facilities, spanning over 29 million square feet of warehouse space, and our owned fleet of over 2,000 MedTrans trucks, enabling us to provide next-day delivery to 95% of our U.S. customers. Our integrated business model and customer-centric culture drives lower costs and better value for our stakeholders. This is the foundation for our durable recurring revenue base, with our net sales having grown every year since inception of the Company at a compound annual growth rate (“CAGR”) of 18%. --- We were founded in 1966 as a med-surg product manufacturer serving the hospital and nursing home sites of care. Through our deep engagement with customers, we recognized a significant gap in the market—our customers were underserved by a fragmented supplier base and faced challenges navigating a complex supply chain. We identified their need for a supply chain partner that was fully integrated, cost-effective, high-quality, and resilient. Our vision was to create a differentiated model that solved these pain points through an integrated company that combined both manufacturing and distribution capabilities and would become a trusted partner to our customers. Twenty-eight years ago, we began augmenting our platform to bring this vision to life: we invested in our distribution capabilities, continued to expand our product portfolio, and adopted the Prime Vendor model. This enabled us to serve a more diverse customer base across multiple end markets, while lowering costs and delivering superior service levels. As a result, Medline is now the largest provider of med-surg products and supply chain solutions serving all points of care, based on total net sales of med-surg products. The combination of our expansive product portfolio and our differentiated supply chain creates a force multiplier for our business. Our Medline Brand segment offers approximately 190,000 products, including those manufactured in our 33 facilities, as well as those sourced from our more than 500 global partners. Our Supply Chain Solutions segment offers approximately 145,000 third-party products and provides customized supply chain optimization services. Our entire product portfolio across our segments is supported by differentiated logistics capabilities and a dedicated and tenured U.S. commercial team of approximately 3,800 people. These capabilities and our compelling value proposition allow us to serve as a long-term strategic partner to our customers and expand the scope of our relationships over time. Our Prime Vendor relationships demonstrate our role as a trusted partner to our customers. In these relationships, we enter into long-term agreements to act as the consolidated distributor and logistics provider for these customers’ med-surg product needs. These partnerships give us visibility into our customers’ purchasing behaviors and demand dynamics, which allows us to anticipate their needs and deliver industry-leading service levels. As these relationships mature, we believe customers increasingly choose Medline Brand products for their superior value. Our Prime Vendor model is reinforced by the flywheel effect within our business where we drive cost savings for Prime Vendor customers, which, over time, supports incremental purchasing of our Medline Brand products and increases our scale. This dynamic allows us to drive further efficiencies by offering superior or similar quality to third-party products at a more cost-effective price. Due to the higher margin we earn on Medline Brand products compared to sales of comparable third-party products, we are able to reinvest in customer value while increasing our profitability. --- Since our founding, we have invested in building a unique customer-centric culture with an entrepreneurial spirit. Our employees are committed to deeply understanding how our customers operate, what challenges they face, and how Medline can better support them. They also understand that relationships are rooted in trust and that we must earn the right to serve our customers every day. We focus on problem solving across the continuum of care and we deploy a team of dedicated customer success representatives to learn the complex needs of our customers. Our creative and collaborative culture consistently earns Medline recognition as a preferred employer, including Newsweek’s Greatest Workplaces, Forbes’ America’s Best Large Employers, and a Chicago Tribune Top Workplace. We have grown our net sales every year by retaining existing customers while gaining share with new and existing customers, with CAGRs of 18% since our founding and approximately 14% over the past 10 years. Notably, nearly 90% of our growth during the past 10 years has been organic. Our product portfolio predominantly consists of consumables, such that approximately 90% of our Medline Brand net sales were recurring for the year ended December 31, 2024. Our business is uniquely resilient during market downturns, as evidenced by our growth through every recession since our founding and during global healthcare crises. For example, our net sales grew at approximately 17% during the 2008-2009 financial crisis and at approximately 11% CAGR during the 2020-2022 COVID-19 pandemic. Not only does our business have a strong track record of results, but we also see significant runway for future sales and earnings growth. We are positioned to grow with our customers as healthcare utilization increases, as they build and acquire new sites, and as they further consolidate med-surg spend with Medline. In addition, we intend to further extend our leading position by adding new Prime Vendor relationships, increasing the number of non-Prime Vendor customers that choose Medline Brand, continuing our channel expansion, developing new products, executing on selective M&A opportunities, and scaling our international footprint. For the nine months ended September 27, 2025, we generated net sales of $20.6 billion, net income of $1.0 billion, and Adjusted EBITDA of $2.7 billion, representing a net income margin of 4.7% and an Adjusted EBITDA Margin of 12.9%. During that period, 48.4% of total net sales and 81.2% of Segment Adjusted EBITDA were generated from our Medline Brand segment, while 51.6% of total net sales and 18.8% of Segment Adjusted EBITDA were generated from our Supply Chain Solutions segment. For the year ended December 31, 2024, we generated net sales of $25.5 billion, net income of $1.2 billion, and Adjusted EBITDA of $3.4 billion, representing a net income margin of 4.7% and an Adjusted EBITDA Margin of 13.2%. During that period, 49.1% of total net sales and 83.5% of Segment Adjusted EBITDA were generated from our Medline Brand segment, while 50.9% of total net sales and 16.5% of Segment Adjusted EBITDA were generated from our Supply Chain Solutions segment. Our principal executive offices are located in Northfield, Illinois.

Market Capitalization
$44.82 billion
P/E Ratio
43.15
Consensus Rating
Moderate Buy
Consensus Price Target
$46.54 (+36.5% Upside)
Volume
7.44 million shares
Average Volume
8.59 million shares
Today's Range
$33.77
▼
$35.02
50-Day Range
$31.64
▼
$36.59
52-Week Range
$31.49
▼
$50.88
Dividend Yield
N/A
Waters stock logo

43. Waters NYSE:WAT

$453.42 -2.17 (-0.48%)
Closing price 10/23/2026 03:59 PM Eastern
Extended Trading
$454.91 +1.49 (+0.33%)
As of 10/23/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. In addition, the company offers MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. Further, the company provides thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by clinical, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company was founded in 1958 and is headquartered in Milford, Massachusetts.

Market Capitalization
$44.57 billion
P/E Ratio
113.07
Consensus Rating
Moderate Buy
Consensus Price Target
$443.79 (-2.1% Downside)
Volume
907,557 shares
Average Volume
881,445 shares
Today's Range
$446.70
▼
$458.16
50-Day Range
$401.78
▼
$458.74
52-Week Range
$282.77
▼
$465.36
Dividend Yield
N/A
IDEXX Laboratories stock logo

44. IDEXX Laboratories NASDAQ:IDXX

$560.38 -6.38 (-1.13%)
Closing price 10/23/2026 04:00 PM Eastern
Extended Trading
$561.05 +0.67 (+0.12%)
As of 10/23/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. More about IDEXX Laboratories

Pros of IDEXX Laboratories

  • IDEXX Laboratories, Inc. recently demonstrated strong financial performance by beating analyst expectations in its most recent earnings report, posting earnings per share of $4.27 against a consensus estimate of $3.94, while also exceeding revenue forecasts with $1.22 billion in sales compared to the expected $1.20 billion.
  • The company has received significant institutional support, with The Goldman Sachs Group initiating coverage with a "buy" rating and a $740.00 price target, which represents a potential upside of over 30% from the current stock price of $566.76.
  • IDEXX Laboratories, Inc. is expanding its technological capabilities through the acquisition of CoVetAI, a move designed to advance veterinary workflow intelligence and broaden its software offerings, which supports its long-term growth strategy in the digital health sector.

Cons of IDEXX Laboratories

  • The stock has experienced a significant decline from its 52-week high of $769.98, currently trading at $566.76, which indicates a substantial drop in market value and potential investor sentiment concerns over the past year.
  • There has been notable insider selling activity, including a recent sale of 2,203 shares by Director Lawrence D. Kingsley and a larger sale of 23,326 shares by CEO Jay Mazelsky earlier in the year, which may signal a lack of confidence from company leadership.
  • Some major institutional investors have reduced their positions, such as Vontobel Holding Ltd., which decreased its holdings by 33.6% during the third quarter, and Curated Wealth Partners LLC, which sold off 99.6% of its stake, suggesting a shift in institutional interest.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$44.15 billion
P/E Ratio
39.41
Consensus Rating
Moderate Buy
Consensus Price Target
$744.09 (+32.8% Upside)
Volume
398,042 shares
Average Volume
515,331 shares
Today's Range
$558.29
▼
$569.56
50-Day Range
$504.70
▼
$566.76
52-Week Range
$500.61
▼
$769.98
Dividend Yield
N/A
BeOne Medicines stock logo

45. BeOne Medicines NASDAQ:ONC

$377.63 -4.64 (-1.21%)
Closing price 10/23/2026 04:00 PM Eastern
Extended Trading
$380.14 +2.51 (+0.67%)
As of 10/23/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Market Capitalization
$41.46 billion
P/E Ratio
66.48
Consensus Rating
Buy
Consensus Price Target
$407.07 (+7.8% Upside)
Volume
315,800 shares
Average Volume
379,866 shares
Today's Range
$372.65
▼
$384.40
50-Day Range
$341.80
▼
$386.46
52-Week Range
$253.95
▼
$388.66
Dividend Yield
N/A
Illumina stock logo

46. Illumina NASDAQ:ILMN

$269.42 +0.02 (+0.01%)
Closing price 10/23/2026 04:00 PM Eastern
Extended Trading
$269.50 +0.08 (+0.03%)
As of 10/23/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. More about Illumina

Pros of Illumina

  • Illumina, Inc. recently launched three early-access capabilities for its BioInsight Platform, including Workflow Orchestrator, DRAGEN Ultra with dnaAI, and Learning Cohorts, which expand the company's AI-driven variant prioritization and genomic-data workflow offerings, potentially increasing the strategic importance of its software and data services beyond traditional hardware and consumables.
  • The company demonstrated strong financial performance in its most recent reported quarter, with earnings per share of $1.31 exceeding the consensus estimate of $1.23 and revenue of $1.16 billion surpassing analyst expectations of $1.13 billion, indicating robust operational execution and a 9.4% year-over-year revenue increase.
  • Illumina, Inc. has raised its full-year 2026 earnings per share guidance to a range of $5.30 to $5.40, which is above the consensus estimate of $5.23, signaling management confidence in sustained growth driven by strong clinical demand and the adoption of its NovaSeq X sequencing systems.

Cons of Illumina

  • Stephens recently downgraded Illumina, Inc. from an "overweight" rating to an "equal weight" rating, reflecting a more cautious view of the stock's risk-reward profile and reducing a potential source of buying pressure from a major research firm.
  • Insiders have been consistently selling shares, with Director Keith Meister selling over 3 million shares in the past six months for an estimated $591 million, and other executives also making sales, which may signal a lack of confidence from those with the most direct knowledge of the company's operations.
  • The stock has experienced volatility due to broader sector sentiment, as it recently fell alongside other AI and genomics-related stocks in a broad technology selloff, indicating that its performance is susceptible to external market forces beyond company-specific news.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$40.68 billion
P/E Ratio
50.26
Consensus Rating
Hold
Consensus Price Target
$234.41 (-13.0% Downside)
Volume
1.26 million shares
Average Volume
2.69 million shares
Today's Range
$264.42
▼
$271.64
50-Day Range
$188.29
▼
$293.69
52-Week Range
$94.00
▼
$309.35
Dividend Yield
N/A
Revolution Medicines stock logo

47. Revolution Medicines NASDAQ:RVMD

$186.99 -0.70 (-0.37%)
Closing price 10/23/2026 04:00 PM Eastern
Extended Trading
$185.93 -1.06 (-0.57%)
As of 10/23/2026 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Market Capitalization
$40.08 billion
P/E Ratio
N/A
Consensus Rating
Moderate Buy
Consensus Price Target
$242.90 (+29.9% Upside)
Volume
1.72 million shares
Average Volume
2.13 million shares
Today's Range
$183.61
▼
$189.52
50-Day Range
$177.96
▼
$221.15
52-Week Range
$53.67
▼
$224.31
Dividend Yield
N/A
Biogen stock logo

48. Biogen NASDAQ:BIIB

$250.69 -3.15 (-1.24%)
Closing price 10/23/2026 04:00 PM Eastern
Extended Trading
$251.12 +0.43 (+0.17%)
As of 10/23/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. More about Biogen

Pros of Biogen

  • Biogen Inc. recently demonstrated strong financial performance by beating analyst expectations in its most recent quarterly report, posting earnings per share of $3.60 against a consensus estimate of $2.94 and generating revenue of $2.74 billion compared to the expected $2.46 billion, which signals robust operational execution and demand for its therapies.
  • The stock has experienced significant momentum, reaching a 52-week high of $254.41 and currently trading at $250.69, reflecting a substantial increase from its 52-week low of $138.00, which indicates strong investor confidence and upward price trajectory over the past year.
  • Biogen Inc. maintains a favorable valuation profile with a P/E ratio of 18.17, which is notably lower than the 44.93 ratio mentioned in some recent analyses, suggesting that the stock may be undervalued relative to its earnings growth and providing a potential margin of safety for investors.

Cons of Biogen

  • Despite the recent price surge, the current stock price of $250.69 is above the consensus price target of $231.07, suggesting that the stock may be overvalued relative to analyst expectations and leaving limited room for further upside based on current estimates.
  • Short interest in Biogen Inc. has been increasing, with shares shorted rising to 5,965,892 as of September 30, 2026, representing a 2.55% month-over-month increase, which indicates that a significant portion of the market is betting against the stock's future performance.
  • The company's earnings guidance for fiscal year 2026 is set at $12.00 to $13.00 per share, which is below the consensus estimate of $13.45, suggesting that management may be cautious about future earnings growth or that the company faces challenges in meeting higher market expectations.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$37.04 billion
P/E Ratio
44.37
Consensus Rating
Moderate Buy
Consensus Price Target
$241.89 (-3.5% Downside)
Volume
1.16 million shares
Average Volume
1.30 million shares
Today's Range
$246.15
▼
$252.44
50-Day Range
$209.15
▼
$253.84
52-Week Range
$138.00
▼
$254.41
Dividend Yield
N/A
Royalty Pharma stock logo

49. Royalty Pharma NASDAQ:RPRX

$63.86 +0.11 (+0.17%)
Closing price 10/23/2026 04:00 PM Eastern
Extended Trading
$63.97 +0.11 (+0.17%)
As of 10/23/2026 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. More about Royalty Pharma

Pros of Royalty Pharma

  • The stock is trading at $63.75, which is near its 52-week high of $64.38, indicating strong recent momentum and investor confidence in the company's performance over the past year.
  • Royalty Pharma plc recently declared a quarterly dividend of $0.2350 per share, which will be paid on December 10th, offering an annualized yield of 1.5% that provides a steady income stream for shareholders.
  • Analysts have consistently raised their price targets, with Morgan Stanley recently increasing its objective to $67.00 and TD Cowen to $68.00, reflecting a consensus "Buy" rating and an average target price of $61.57 that suggests further upside potential.

Cons of Royalty Pharma

  • Insiders have been actively selling shares, with EVP Christopher Hite selling 100,000 shares in September and EVP Marshall Urist selling 4,126 shares in October, which may signal that company executives are taking advantage of the current high stock prices to reduce their personal exposure.
  • Despite beating earnings estimates, the company's revenue of $674.14 million in the last quarter fell short of analyst expectations of $758.93 million, suggesting that top-line growth may be slowing or facing headwinds in the pharmaceutical market.
  • The company has a debt-to-equity ratio of 0.88, which indicates a significant level of leverage relative to its equity, potentially increasing financial risk if interest rates remain high or if royalty income streams face unexpected disruptions.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$36.72 billion
P/E Ratio
44.04
Consensus Rating
Buy
Consensus Price Target
$61.57 (-3.6% Downside)
Volume
4.02 million shares
Average Volume
3.02 million shares
Today's Range
$63.01
▼
$63.97
50-Day Range
$56.21
▼
$63.96
52-Week Range
$35.92
▼
$64.38
Dividend Yield
1.47%
ResMed stock logo

50. ResMed NYSE:RMD

$252.79 -0.27 (-0.11%)
Closing price 10/23/2026 03:59 PM Eastern
Extended Trading
$252.84 +0.06 (+0.02%)
As of 10/23/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. More about ResMed

Pros of ResMed

  • ResMed Inc. recently launched the AirTouch F40 full-face fabric CPAP mask in the U.S. on October 19, 2026, which is designed to provide greater comfort and choice for patients with obstructive sleep apnea, potentially driving long-term therapy adherence and product demand.
  • The company demonstrated strong financial performance in its most recent reported quarter, posting earnings per share of $2.95, which exceeded the consensus estimate of $2.89, while revenue reached $1.46 billion, representing an 8.6% year-over-year increase.
  • ResMed Inc. recently increased its quarterly dividend to $0.66 per share, paid on September 24, 2026, which represents a boost from the previous $0.60 payment and offers investors a current dividend yield of approximately 1.07%.

Cons of ResMed

  • The consensus rating from sell-side analysts is currently "Hold," with nine analysts issuing hold ratings and seven issuing buy ratings, and the average price target of $243.23 is below the current stock price of $253.31, suggesting limited upside potential.
  • Insider selling has been consistent, with CEO Michael Farrell selling 4,991 shares on October 7, 2026, and Director Peter Farrell selling 970 shares on September 2, 2026, both executed under pre-arranged Rule 10b5-1 trading plans.
  • Several major financial institutions have recently lowered their price targets or maintained neutral stances, including Piper Sandler lowering its target to $225.00 and Wells Fargo cutting its target to $215.00 in August 2026, reflecting cautious sentiment among key brokers.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$35.56 billion
P/E Ratio
24.24
Consensus Rating
Hold
Consensus Price Target
$243.23 (-3.8% Downside)
Volume
1.01 million shares
Average Volume
1.09 million shares
Today's Range
$248.72
▼
$255.57
50-Day Range
$218.28
▼
$253.31
52-Week Range
$180.26
▼
$277.67
Dividend Yield
1.04%